India is the core. The risks are closer than they look.

A growing Indian MedTech company was expanding aggressively - adding 20 to 30 new dealers and distributors every month across Tier 2 and Tier 3 cities. The sales team was under pressure to hit coverage targets, and demanding financial documentation from a small-town dealer before they'd even placed a first order felt like a deal-killer. So the standard became: a KYC form, a cancelled cheque, and a GST number. What the company didn't have was any view of the dealer's financial strength, existing liabilities, or creditworthiness. Some of these dealers were solid businesses. Others were thin operations that had taken on more stock than their working capital could support. The company had no way to tell them apart at the time of onboarding - and by the time the difference became clear, consignment stock was already in the field.

Distributor Performance Management runs an automated credit risk assessment the moment a new dealer is added - pulling from GST filing history, MCA records, credit bureau data, court filings, and payment network signals to produce a financial strength profile within hours, not days. Dealers are assigned a risk tier that informs the credit limit and consignment value extended from day one. Companies don't have to choose between moving fast and knowing who they're dealing with.

The sales team can onboard at speed while the credit team gets an objective risk tier for every new dealer - not a binary approve/reject, but a calibrated starting position. High-potential dealers in genuinely strong financial shape get fuller credit lines from the start. Weaker profiles get smaller initial limits with defined review triggers, reducing the company's exposure without turning away business it wants to win.

Most Indian MedTech distributors are family-run businesses operating on tight working capital - financing consignment stock from their own cash flow while waiting on hospital collections. When a major hospital delays payment or a competing product undercuts their margin, the first sign the manufacturer sees is a slower remittance cycle. By the time the delay is flagged internally, outstanding dues have often built up across two or three months. The sales team, protective of the relationship, reports it as a temporary blip.

Distributor Performance Management tracks financial signals across the distributor base continuously - payment behaviour, credit bureau data, court filings, GST compliance status, and local news. Risk alerts are ranked by outstanding exposure so the credit team always knows which distributor relationships need immediate attention, independent of what the sales team is reporting.

Credit managers have an objective, data-backed view of each distributor's financial health that does not depend on relationship-based reporting. Deteriorating accounts are flagged weeks before they become overdue, giving the company time to tighten terms or restructure the arrangement before the relationship sours.

Under Indian medical device regulations, distributors must hold valid CDSCO registration and state drug licences to sell notified medical devices. When a distributor comes under financial pressure, regulatory renewal fees are among the first costs they defer. A MedTech company discovered during a CDSCO inspection that one of their regional distributors had been selling on an expired licence for over five months - creating regulatory exposure for the manufacturer and grounds for product seizure in that territory.

Distributor Performance Management tracks compliance status alongside financial health - monitoring CDSCO registration validity, state drug licence renewals, and GST filing regularity as part of the continuous monitoring view. Financial stress and compliance deterioration almost always move together; seeing both in one place is the difference between catching it early and reading about it in an inspection report.

Regulatory teams get an automated alert when a distributor's licence status changes or approaches expiry - without depending on the distributor to self-report. Corrective action happens before product moves on an invalid licence, not after an inspection finds it.

Consignment-based selling is standard in Indian MedTech - devices are placed at the hospital, billed only when used, and returned if unused or if the procedure changes. In practice, returns from a single hospital can become a persistent pattern: procedures rescheduled, implants substituted at the last moment, or stock that sits in a hospital store and comes back damaged. Each return is processed individually by the field team; nobody adds them up at the account level. By year-end, one hospital might account for a disproportionate share of the company's total returns - a signal that something structural is wrong, whether around clinical preference, billing disputes, or procurement irregularities.

Large Customer Risk Assessment aggregates transaction, billing, and returns data at the hospital level - flagging accounts where return rates, dispute frequency, or payment irregularities are trending outside the norm for that customer type. A pattern that is invisible transaction-by-transaction becomes clear when viewed as a customer risk profile over time.

Sales and finance teams get a regular view of which hospital accounts are generating disproportionate returns or disputes - enabling them to investigate the root cause (clinical, commercial, or operational) and address it before it becomes a write-off or a strained relationship.

Government hospital tenders - through state health departments, ESIC, CGHS, and procurement agencies like GeM - represent a significant and growing revenue channel for Indian MedTech companies. Payment cycles through these channels are rarely predictable. State budget constraints, retendering delays, and administrative backlogs mean invoices can sit for six to nine months without escalation. Because each state account is managed by a separate field team, the company's actual aggregated exposure to slow-paying government institutions is rarely visible to the CFO until it surfaces in a working capital conversation.

Large Customer Risk Assessment consolidates exposure across all government hospital accounts - state health departments, central procurement agencies, and individual hospital entities - into a single receivables risk view. Payment cycle trends are tracked per institution, and ageing buckets are flagged against provisioning thresholds before they reach audit-triggering levels.

The CFO gets a consolidated government receivables dashboard segmented by state, institution type, and ageing - without relying on field team reports that tend to understate the problem. Provisioning decisions are made ahead of quarter close, not forced by auditors at year-end.

A MedTech manufacturer sourced a precision-machined titanium component from a small, highly specialised supplier in Pune - one of very few domestic manufacturers with the required ISO 13485 certification. The supplier had been reliable for three years. When a larger customer defaulted on payment to the supplier, it triggered a cascade: the supplier stopped paying sub-vendors, missed a bank EMI, and within weeks had suspended operations. The MedTech company had two weeks of buffer stock and no qualified alternative. Importing an equivalent component would take 10–12 weeks and require fresh CDSCO validation.

Vendor Due Diligence monitors the financial health of critical suppliers continuously - tracking payment behaviour, banking signals, court filings, GST compliance, and news. Sole-source and single-supplier dependencies are flagged as concentration risks in the portfolio view, prompting proactive qualification of alternatives before a crisis forces the issue.

The supplier's financial deterioration becomes visible months before the operational failure - giving procurement time to either support the supplier through a difficult period or begin parallel qualification with a backup, on a timeline they choose rather than one forced by a production stoppage.

A MedTech company had outsourced the manufacture of a product line to a contract manufacturer in Ahmedabad - a well-regarded facility with consistent audit results. What the quality audits did not reveal was that the OEM was under significant working capital pressure: GST returns were being filed late, a term loan had been restructured, and the promoter had pledged personal assets as collateral. When the OEM requested a 45-day advance payment against a purchase order - framed as a routine cash flow bridge - it was the first signal the company received that anything was wrong.

Vendor Due Diligence monitors OEM partners across financial and compliance dimensions that quality audits do not cover - GST filing regularity, MCA filings, credit bureau signals, loan restructuring events, and promoter-level financial indicators. The financial picture and the quality picture are tracked together, not in separate cycles that never intersect.

The OEM's working capital stress becomes visible months before the advance payment request - giving the company time to assess the situation calmly, restructure payment terms if appropriate, or begin a quiet parallel qualification rather than managing it as a production emergency.

An Indian MedTech company with CE-marked products had supplied the European market through a distributor for years without issue. When EU MDR and CSRD reporting requirements tightened, their European distributor requested full ESG assessments for every supplier in the manufacturing chain - raw materials, components, and sub-contractors. The company had 180+ active suppliers, formal documentation for fewer than 25, and no structured process to produce the rest. The distributor's deadline was 90 days. The same quarter, an investor sent an ESG questionnaire and the company received a BRSR disclosure requirement from their auditor.

Sustainability Assessment generates ESG scores, emissions estimates, and compliance flags for suppliers using third-party data - covering the gap where self-reporting is absent. For Indian suppliers with limited ESG disclosure, Privue draws on alternative data sources to produce defensible assessments structured against EU MDR, CSRD, and BRSR frameworks, with a full audit trail suitable for all three disclosures.

The company delivered documented ESG assessments across 90% of their supplier base within eight weeks - well within the distributor's deadline. The same underlying dataset served the investor ESG questionnaire and BRSR disclosure, avoiding three separate data-gathering exercises running in parallel.